Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tozadenant (SYN115) 是 A2A 腺苷受体拮抗剂,对人和恒河猴的 Ki 分别为 11.5 和 6 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 328 | 现货 | ||
2 mg | ¥ 465 | 现货 | ||
5 mg | ¥ 745 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,480 | 现货 | ||
50 mg | ¥ 3,580 | 现货 | ||
100 mg | ¥ 5,370 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 818 | 现货 |
产品描述 | Tozadenant (SYN115) is an adenosine A2A receptor antagonist(Ki of 11.5 nM and 6 nM on human and rhesus,respectively) |
靶点活性 | A2A receptor (rhesus):6 nM(Ki), A2A receptor (human):11.5 nM(Ki) |
体内活性 | When compared to the drugs tested alone, Radiprodil and Tozadenant combination led to a significant increase of motor activity and an improvement of motor disability in MPTP-treated marmosets. In addition, the motor restoration brought about by the combination was almost completely devoid of dyskinesia[1] |
动物实验 | Before initiating the Radiprodil & Tozadenant combination experiment, 14 primates were challenged with a dose of 8 mg/kg (po) of L-Dopa and behaviour was recorded for 5 hours. This "Pre-L-Dopa-test" was used to select the 12 subjects required for the study. Their response to the L-Dopa challenge was subsequently used as a comparator to the ensuing response to the different drug treatments and combinations. The effects of the drugs alone or in combination were assessed after acute oral gavage.This experiment investigated the effects on motor deficits of Radiprodil plus Tozadenant twice daily at an interval of 5 hrs according to a modified Latin square design in n = 12 MPTP-treated marmosets. At the time of the second drugs administration a novel object (cotton reel, table tennis ball) was placed into the cage. The four different treatments were (1) Tozadenant (150 mg/kg) plus Radiprodil (2.0 mg/kg), (2) Tozadenant (150 mg/kg) plus vehicle, (3) Radiprodil (2.0 mg/kg) plus vehicle, (4) vehicle[1]. |
别名 | SYN115, 4-羟基-N-[4-甲氧基-7-(4-吗啉基)-2-苯并噻唑基]-4-甲基-1-哌啶甲酰胺 |
分子量 | 406.5 |
分子式 | C19H26N4O4S |
CAS No. | 870070-55-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (123.00 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.46 mL | 12.3001 mL | 24.6002 mL | 61.5006 mL |
5 mM | 0.492 mL | 2.46 mL | 4.92 mL | 12.3001 mL | |
10 mM | 0.246 mL | 1.23 mL | 2.46 mL | 6.1501 mL | |
20 mM | 0.123 mL | 0.615 mL | 1.23 mL | 3.075 mL | |
50 mM | 0.0492 mL | 0.246 mL | 0.492 mL | 1.23 mL | |
100 mM | 0.0246 mL | 0.123 mL | 0.246 mL | 0.615 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tozadenant 870070-55-6 GPCR/G Protein Neuroscience Adenosine Receptor P1 receptor SYN 115 SYN115 SYN-115 Inhibitor 4-羟基-N-[4-甲氧基-7-(4-吗啉基)-2-苯并噻唑基]-4-甲基-1-哌啶甲酰胺 inhibit inhibitor